Ocular surface and external filtration surgery: Mutual relationships

Developments in Ophthalmology

Volumn 50, Issue , 2012, Pages 64-78

  Baudouin, Christophe ^a,b  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; CONJUNCTIVA; CORNEA; FILTERING OPERATION; GLAUCOMA; HUMAN; METHODOLOGY; PATHOLOGY; POSTOPERATIVE COMPLICATION; SURFACE PROPERTY;

ANIMALS; CONJUNCTIVA; CORNEA; FILTERING SURGERY; GLAUCOMA; HUMANS; POSTOPERATIVE COMPLICATIONS; SURFACE PROPERTIES;

EID: 84860874311     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000334791     Document Type: Article

References (55)

1. European Glaucoma Society: Terminology and Guidelines for Glaucoma, ed 3. Savona, Dogma, 2008.
2. Lama P, Fechtner RD: Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48:314-346. (Pubitemid 36549254)
3. Broadway DC, Grierson I, OBrien C, Hitchings RA: Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437-1445. (Pubitemid 24350506)
4. Broadway DC, Grierson I, OBrien C, Hitchings RA: Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-1454. (Pubitemid 24350507)
5. Baudouin C, Labb?A, Liang H, Pauly A, Brignole-Baudouin F: Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29:312-334.
6. Pisella PJ, Pouliquen P, Baudouin C: Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-423. (Pubitemid 34293291)
7. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T: Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:341-349. (Pubitemid 47056287)
8. Erb C, Gast U, Schremmer D: German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 2008;246:1593-1601.
9. Leung EW, Medeiros FA, Weinreb RN: Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-355.
10. Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A: Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010;88:329-336.
11. Sherwood MB, Grierson I, Millar L, Hitchings RA: Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenons capsule in glaucomatous patients. Ophthalmology 1989;96: 327-335. (Pubitemid 19078905)
12. Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, B?hetoille A: Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-563. (Pubitemid 30191592)
13. Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM: Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 1992;99:197-202.
14. Thorne JE, Anhalt GJ, Jabs DA: Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 2004;111:45-52. (Pubitemid 38032209)
15. Nuzzi R, Vercelli A, Finazzo C, Cracco C: Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 1995;233: 154-162.
16. Pozarowska D, Toczo?owski J, Wo?niak F: The evaluation of morphological status of bulbar conjunctiva after long-term antiglaucoma drug therapy. Klin Oczna 1999;101:455-458.
17. Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL: Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol 1991;112:297-301.
18. Herreras JM, Pastor JC, Calonge M, Asensio VM: Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082-1088.
19. Hong S, Lee CS, Seo KY, Seong GJ, Hong YJ: Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol 2006:142;185-186. (Pubitemid 43946804)
20. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P: Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994;101:454-460. (Pubitemid 24100569)
21. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C: Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-1368. (Pubitemid 38859312)
22. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F: Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004;111:2186-2192. (Pubitemid 39575587)
23. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F: The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-115.
24. Souchier M, Buron N, Lafontaine PO, Bron AM, Baudouin C, Creuzot-Garcher C: Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery? Br J Ophthalmol 2006;90:1366-1369. (Pubitemid 44702061)
25. Leal BC, Medeiros FA, Medeiros FW, Santo RM, Susanna R Jr: Conjunctival hyperemia associated with bimatoprost use: a histopathologic study. Am J Ophthalmol 2004;138:310-313. (Pubitemid 39037447)
26. Rodrigues Mde L, Felipe Crosta DP, Soares CP, Deghaide NH, Duarte R, Sakamoto FS, Furtado JM, Paula JS, Donadi EA, Soares EG: Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment. J Glaucoma 2009;18:197-200.
27. Ishibashi T, Yokoi N, Kinoshita S: Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003;12:486-490. (Pubitemid 37494177)
28. Baudouin C, de Lunardo C: Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42. (Pubitemid 28176961)
29. Rolando M, Brezzo V, Giordano G, Campagna P, Burlando S, Calabria G: The effect of different benzalkonium chloride concentrations on human normal ocular surface; in Van Bijsterveld O, Lemp M, Spinelli D (eds): The Lacrimal System. Kugler and Ghedini, Amsterdam, 1991.
30. Nuzzi R, Finazzo C, Cerruti A: Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal response. Int Ophthalmol 1998;22:31-35. (Pubitemid 29083233)
31. Ciancaglini M, Carpineto P, Agnifili L, Nubile M, Fasanella V, Lanzini M, Calienno R, Mastropasqua L: An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur J Ophthalmol 2008;18:400-407.
32. Martone G, Frezzotti P, Tosi GM, Traversi C, Mittica V, Malandrini A, Pichierri P, Balestrazzi A, Motolese PA, Motolese I, Motolese E: An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009;147: 725-735.
33. Brandt JD: Does benzalkonium chloride cause cataract? Arch Ophthalmol 2003;121:892-893. (Pubitemid 36676228)
34. Miyake K, Ibaraki N, Goto Y, Oogiya S, Ishigaki J, Ota I, Miyake S: ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy. J Cataract Refract Surg 2003;29:1800-1810. (Pubitemid 37210621)
35. Champeau E, Edelhauser H: Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate; in Holly F (ed): The Preocular Tear Film. Dry Eye Institute, Lubbock, 1986.
36. Broadway DC, Chang LP: Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma 2001;10:237-249. (Pubitemid 32553589)
37. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA: The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108: 1543-1548. (Pubitemid 20377540)
38. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, Tube Versus Trabeculectomy Study Group: Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol 2009; 148:670-684.
39. Helin M, R?kk?S, Puustj?vi T, Ter?virta M, Ollikainen M, Uusitalo H: Conjunctival inflammatory cells and their predictive role for deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma. J Glaucoma 2011;20:172-178.
40. Broadway DC, Grierson I, St?mer J, Hitchings RA: Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol 1996;114: 262-267. (Pubitemid 26086730)
41. Baudouin C, Nordmann JP, Denis P, Creuzot-Garcher C, Allaire C, Trinquand C: Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol 2002;240:929-935. (Pubitemid 36097117)
42. Breusegem C, Spielberg L, Van Ginderdeuren R, Vandewalle E, Renier C, Van de Veire S, Fieuws S, Zeyen T, Stalmans I: Preoperative nonsteroidal antiinflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology 2010;117:1324-1330.
43. Shield MB, Scroggs MW, Sloop CM, Simmons RB: Histopathologic observation concerning hypotony after trabeculectomy with adjunctive mitomycin-C. Am J Ophthalmol 1993;116:673-683. (Pubitemid 23356532)
44. Hutchinson AK, Grossniklaus HE, Brown RH, McManus PE, Bradley CK: Clinicopathologic features of excised mitomycin filtering blebs. Arch Ophthalmol 1994;112:74-79. (Pubitemid 24024504)
45. Powers TP, Stewart WC, Stroman GA: Ultrastructural features of filtering blebs with different clinical appearances. Ophthalmic Surg Lasers 1996;27: 790-794.
46. Vesti E: Filtering blebs: follow up of trabeculectomy. Ophthalmic Surg 1993;24:249-255. (Pubitemid 23131443)
47. Picht G, Grehn F: Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol 1998;9:2-8. (Pubitemid 28284566)
48. Sacu S, Rainer G, Findl O, Georgopoulos M, Vass C: Correlation between the early morphological appearance of filtering blebs and outcome of trabeculectomy with mitomycin C. J Glaucoma 2003;12: 430-435. (Pubitemid 37237375)
49. Amar N, Labb?A, Hamard P, Dupas B, Baudouin C: Filtering blebs and aqueous pathway an immunocytological and in vivo confocal microscopy study. Ophthalmology 2008;115:1154-1161.
50. Labb?A, Dupas B, Hamard P, Baudouin C: In vivo confocal microscopy study of blebs after filtering surgery. Ophthalmology 2005;112:1979-1986.
51. Picht G, Grehn F: Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol 1998;9:2-8. (Pubitemid 28284566)
52. Chiou AG, Mermoud A, Underdahl JP, Schnyder CC: An ultrasound biomicroscopic study of eyes after deep sclerectomy with collagen implant. Ophthalmology 1998;105:746-750. (Pubitemid 28180229)
53. Ciancaglini M, Carpineto P, Agnifili L, Nubile M, Lanzini M, Fasanella V, Mastropasqua L: Filtering bleb functionality: a clinical, anterior segment optical coherence tomography and in vivo confocal microscopy study. J Glaucoma 2008;17:308-317.
54. Kawana K, Kiuchi T, Yasuno Y, Oshika T: Evaluation of trabeculectomy blebs using 3-dimensional cornea and anterior segment optical coherence tomography. Ophthalmology 2009;116:848-855.
55. Nakano N, Hangai M, Nakanishi H, Inoue R, Unoki N, Hirose F, Ojima T, Yoshimura N: Early trabeculectomy bleb walls on anterior-segment optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2010;248:1173-1182.